| emtricitabine/tenofovir disoproxil fumarate / Generic mfg. |
ACTRN12616001387415: NZ PrEP: A study assessing the feasibility,risks and benefits of prescribing daily Truvada in a sample of men who are at high risk of acquiring HIV |
|
|
| Recruiting | 4 | 150 | | | Auckland District Health Board, Gilead Sciences | HIV | | | | |
ChiCTR-OPC-16009603: A preliminary study on the delivery of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) at high risk of HIV transmission through the application of a self-financed incentivized approach |
|
|
| Recruiting | 4 | 70 | | HIV prevention / Daily pre-exposure prophylaxis / truvada; Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg), 1 tablet, 30 weeks, daily | Stanley Ho Centre for Emerging Infectious Diseases; Level of the institution：, Council for the AIDS Trust Fund | HIV infection | | | | |
ChiCTR1800016100: Pre-exposure prophylaxis with on-demand versus daily TDF/FTC in men who have sex with men at high risk of HIV infection – a crossover study |
|
|
| Not yet recruiting | 4 | 90 | | Truvada tablet (Tenofovir 300 mg / Emtricitabine 200 mg): 1 tablet daily versus 2 tablets before sex, and 1 tablet at 24 and then 48 hours afterwards, for 16 weeks | Stanley Ho Centre for Emerging Infectious Diseases; Level of the institution：, AIDS Trust Fund | HIV infection | | | | |
2011-004935-30: Study “before-after”: Adherence Evaluation to antiretroviral therapy administered in two different ways Studio ''before-after'' di valutazione dell'aderenza di due diverse modalita' di somministrazione della terapia antiretrovirale |
|
|
| Ongoing | 4 | 400 | Europe | Film-coated tablet, EPIVIR*FL 30CPR RIV 300MG, VIREAD*30CPR 245MG, ZIAGEN*6BLISTER 10CPR 300MG, SUSTIVA*30CPR RIV 600MG BLIST, RETROVIR*60CPR 300MG, TRUVADA*30CPR RIV 200MG/245MG, KIVEXA*BL 30CPR RIV 600MG+300M, COMBIVIR*60CPR RIV 150MG+300MG, ATRIPLA*30CPR RIV600+200+245MG | U.L.S.S. 9 DI TREVISO, studio no profit, farmaci a carico del SSN | HIV infection Infezione da HIV, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2011-005270-35: Study of the effect of pregnancy on the concentrations of antiretroviral drugs in the blood of women with HIV infection Studio dell'effetto della gravidanza sulle concentrazioni dei farmaci antiretrovirali nel sangue di donne con infezione da HIV |
|
|
| Ongoing | 4 | 120 | Europe | Tablet, Capsule, soft, Capsule, hard, Film-coated tablet, VIRAMUNE*60CPR 200MG, COMBIVIR*FL 60CPR RIV, KALETRA*120CPR RIV 200MG+50MG, REYATAZ*60CPS 150MG, TRUVADA*30CPR RIV 200MG/245MG, PREZISTA*60CPR RIV 600MG, ISENTRESS*FL 60CPR RIV 400MG, NORVIR*FL 84CPS MOLLI 100MG | ISTITUTO NAZIONALE DELLE MALATTIE INFETTIVE LAZZARO SPALLANZANI, Istituto Superiore di Sanita' | HIV-1 infection Infezione da HIV-1, HIV infection Infezione da HIV, Diseases [C] - Virus Diseases [C02] | | | | |
| Ongoing | 4 | 22 | Europe | Tivicay, Isentress, Truvada, Film-coated tablet, Tivicay, Isentress, Truvada | Imperial College London | Human Immunodificiency Virus, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-004015-36: Role of a switch to an once-daily regimen of antiretroviral therapy on HIV-DNA levels and immune activation. Effetti del passaggio a un regime HAART in unica somministrazione giornaliera sui livelli di HIV-DNA e dei livelli di attivazione immunitaria. |
|
|
| Ongoing | 4 | 30 | Europe | STRIBILD, Film-coated tablet, STRIBILD | AZIENDA OSPEDALIERA SAN PAOLO, Gilead Sciences S.r.l. | Human Immunodeficiency Virus (HIV-1) Infection Infezione da virus dell’immunodeficienza umana (HIV1), HIV virus Infection Infezione da virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2015-000274-35: clinical trial to assess the safety, tolerability and efficacy of two dolutegravir-based simplification strategies in HIV-infected patients with prolonged virological suppression. ENSAYO CLÍNICO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD Y EFICACIA DE DOS ESTRATEGIAS DE SIMPLIFICACIÓN BASADAS EN DOLUTEGRAVIR EN PACIENTES INFECTADOS POR VIH CON SUPRESIÓN VIROLÓGICA SOSTENIDA. |
|
|
| Ongoing | 4 | 450 | Europe | Lamivudine, Efavirenz, nevirapine, J05AX12, Coated tablet, Capsule, hard, Tablet, Prolonged-release tablet, Tivicay, Stribild, TRUVADA, KIVEXA, ZIAGEN, VIREAD, EMTRIVA, ATRIPLA, EVIPLERA, ISENTRESS, RAYATAZ, PREZISTA, KALETRA, NORVIR, INTELENCE, EDURANT, TRIUMEQ | Fundació Lluita contra la SIDA, Fundació Lluita contra la SIDA | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH)., HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2013-004809-24: The role of Home packs of HIV PEPSE in High Risk Individuals |
|
|
| Ongoing | 4 | 140 | Europe | Film-coated tablet, Celsentri (Trial Arm A), Truvada (Trial Arm A), Celsentri (Trial Arm B), Truvada (Trial Arm B) | Guy's & St. Thomas' NHS Foundation Trust, Viiv Healthcare UK Ltd, Gilead Sciences Ltd | HIV, HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-002569-32: HIV prevention for men who have sex with men using medication HIV preventie voor mannen die seks hebben met mannen met behulp van medicijnen |
|
|
| Ongoing | 4 | 370 | Europe | truvada, Tablet, Truvada | Academic Medical Center, PHSA | prevention of HIV infection HIV infectie preventie, prevention of HIV infection HIV infectie preventie, Health Care [N] - Environment and Public Health [N06] | | | | |
2005-004021-26: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic regimen - Tenefovir/Emtricitabine (Truvada) plus Efavirenz. |
|
|
| Ongoing | 4 | 60 | Europe | Efavirenz, AZT/3TC, emtricitabine/tenofovir, SUSTIVA, COMBIVIR, TRUVADA, SUSTIVA, COMBIVIR, TRUVADA | University Hospital Birmingham | HIV | | | | |
2006-006174-19: A randomised, open label, phase IV comparative study to determine the effects on renal function of continuing treatment with tenofovir versus replacement with abacavir in HIV positive persons |
|
|
| Ongoing | 4 | 30 | Europe | Ziagen, Viread, Truvada, Kivexa, Not appllicable, Not applicable, Not appilcable, Ziagen, Viread, Truvada, Kivexa, Ziagen, Viread, Truvada, Kivexa | St Stephens AIDS Trust | HIV | | | | |
2007-003066-18: Estudio piloto, aleatorizado, nacional, multicéntrico, de eficacia inmunológica, comparando un régimen TARGA de tres fármacos (Tenofovir + Emtricitabina + Lopinavir/r) y cuatro fármacos (Tenofovir + Emtricitabina + Zidovudina + Lopinavir/r) en primera línea para el tratamiento de pacientes con infección por VIH avanzada |
|
|
| Ongoing | 4 | 92 | Europe | Kaletra, Truvada, Kaletra, Truvada, Zidovudina, Kaletra, Truvada, Zidovudina | Dr. Miguel Cervero | Pacientes diagnosticados de infección por VIH con CD4 < 100 células/microlitro, que comienzan por primera vez tratamiento antirretrovial. | | | | |
2009-011816-39: A randomised, open label, prospective study to assess two different therapeutic strategies following first treatment failure in HIV-1 infected subjects.‘The First Failure Study’ : ‘FAST’ |
|
|
| Ongoing | 4 | 44 | Europe | Etravirine, Darunavir, Truvada, Ritonavir, Intelence, Prezista, Truvada, Norvir, Intelence, Prezista, Truvada, Norvir | Imperial College London | HIV | | | | |
2010-023264-40: Efficacy in the central nervous system (CNS) of two combination regimens with different penetration rank in HIV-positive na�ve patients |
|
|
| Ongoing | 4 | 32 | Europe | KALETRA, KIVEXA, REYATAZ, TRUVADA, NORVIR, KALETRA, KIVEXA, REYATAZ, TRUVADA, NORVIR | AZIENDA OSPEDALIERA S. GERARDO DI MONZA | HIV infection | | | | |
2010-022202-41: ESTUDIO PILOTO DEL CAMBIO EN LA ACTIVIDADANTIRRETROVIRAL EN SISTEMA NERVIOSO CENTRAL TRAS LA SUSTITUCIÓN DE TDF/FTC/EFV POR ABC/3TC/MVC |
|
|
| Ongoing | 4 | 15 | Europe | CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película, CELSENTRI 150 mg comprimidos recubiertos con película, ATRIPLA 600 mg/245 mg comprimidos recubiertos con película, KIVEXA 600 mg/300 mg comprimidos recubiertos con película | Daniel Podzamczer | Virus de imunodeficiencia humana-1 | | | | |
2011-003447-21: Randomised controlled trial of the tolerability and completion of maraviroc compared to Kaletra© in combination with Truvada© for HIV post-exposure prophylaxis |
|
|
| Ongoing | 4 | 280 | Europe | Maraviroc, Celsentri, Celsentri | Camden Provider Services, Pfizer | Prophylaxis and prevention of HIV Infection. | | | | |
2012-003595-39: A clinical trial to compare brain function and neurocognitive performance in antiretroviral treatments with different levels of penetration in the central nervous system. Ensayo clínico para comparar el funcionamiento cerebral y rendimiento neurocognitivo en tratamientos antirretrovirales con distintos niveles de penetracion en el sistema nervioso central. |
|
|
| Ongoing | 4 | 40 | Europe | ATAZANAVIR, Reyataz, Norvir, Kivexa, Sustiva, Truvada, Reyataz, Norvir, Kivexa, Sustiva, Truvada | Fundación para la Investigación Biomédica del Hospital Universitario La Paz, Fundacion para la Investigacion Biomédica del Hospital Universitario La Paz | Patients infected with human immunodeficiency virus who have never received antiretroviral treatment. Pacientes infectados con virus de inmunodeficiencia humana que nunca han recibido tratamiento antirretroviral. | | | | |
2015-005297-37: Bone Evaluation in women over 40 who Switch from Truvada/NNRTI to Triumeq |
|
|
| Ongoing | 4 | 90 | Europe | Tenofovir, Lamivudine, Efavirenz, Nevirapine, Etravirine, Rilpivirine, Film-coated tablet, Tablet, Triumeq, Truvada, Atripla, Eviplera | King's College Hospital NHS Foundation Trust, ViiV Healthcare Ltd | Human Immunodeficiency Virus, People infected with Human Immunodeficiency Virus (HIV), Diseases [C] - Immune System Diseases [C20] | | | | |
2012-000198-21: A study to assess the efficacy and safety of the withdrawal of nucleos/tide analogues with resistance in multitreated HIV-1-infected subjects with virological suppression ESTUDIO SOBRE LA EFICACIA Y SEGURIDAD DE LA RETIRADA DE ANÁLOGOS DE NUCLEÓS/TIDO CON RESISTENCIA EN SUJETOS CON INFECCIÓN POR VIH-1 MULTITRATADOS Y CON SUPRESIÓN VIROLÓGICA. |
|
|
| Ongoing | 4 | 292 | Europe | Epivir, Emtriva, Retrovir, Zerit, Viread, Ziagen, Combivir, Trizivir, Kivexa, Truvada, Videx, Epivir, Emtriva, Retrovir, Zerit, Viread, Ziagen, Combivir, Trizivir, Kivexa, Truvada, Videx | Fundació Lluita contra la SIDA, Ministerio de Sanidad, Política Social e Igualdad (Investigación Independiente) | Infection with human immunodeficiency virus (HIV). Infección por el virus de la inmunodeficiencia humana (VIH). | | | | |
| Not yet recruiting | 4 | 60 | Europe | Tivicay 50 mg film - coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets, Film-coated tablet, Tivicay 50 mg film-coated tablets, Isentress 400 mg Film-coated Tablets, Truvada 200 mg/245 mg film-coated tablets, Stribild 150 mg/150 mg/200 mg/245 mg film-coated tablets | St Stephen's AIDS Trust, Merck, Sharp & Dohme Limited | HIV | | | | |
2016-005078-37: A study to reduce the risk of sexually acquired HIV-1 in adults at high risk. |
|
|
| Ongoing | 4 | 100 | Europe | Truvada (emtricitabine and tenofovir disoproxil fumarate), Truvada(emtricitabine&tenofovirdisoproxil fumarate, Film-coated tablet, Truvada | Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases, Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases | Healthy volunteers, Healthy volunteers, Diseases [C] - Virus Diseases [C02] | | | | |
2017-000469-62: Pilot single‐arm clinical trial to evaluate the efficacy, PK interactions and safety of dolutegravir plus 2 NRTIs in HIV‐1‐infected solid organ transplant patients. DGT-SOT Ensayo clínico piloto de un brazo para evaluar la eficacia, las interacciones farmacocinéticas y la seguridad del dolutegravir más 2 inhibidores nucleósidos de la Transcriptasa Inversa (NRTIs en su siglas en inglés) en pacientes trasplantados de órganos sólidos infectados por el VIH-1. DGT-SOT |
|
|
| Ongoing | 4 | 20 | Europe | Triumeq 50 mg/600 mg/300 mg comprimidos recubiertos con película dolutegravir/abacavir/lamivudina, Tivicay 50 mg, Truvada comprimidos recubiertos con película., Coated tablet, Tablet, Triumeq®, Dolutegravir 50 mg, 200 mg de emtricitabina y 245 mg de tenofovir disoproxil (equivalente a 300 mg de tenofovir disoproxil fumarato ó 136 mg de tenofovir). | Fundació Clínic per a la Recerca Biomèdica, ViiV Healthcare | HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., HIV-1 infected solid organ transplant patients pacientes trasplantados de órganos sólidos infectados por el VIH-1., Diseases [C] - Virus Diseases [C02] | | | | |
2017-002855-27: BonE health in ageING Women: Improvement or prevention of changes in Bone MineralDensity by Switching Antiretroviral Agents. Is there an optimal time to intervene? La salute delle ossa nell¿invecchiamento femminile: miglioramento o prevenzione delle variazioni di densit¿ minerale ossea modificando i farmaci antiretrovirali. Esiste un momento ottimale per intervenire? |
|
|
| Not yet recruiting | 4 | 128 | Europe | truvada, stribild, eviplera, genvoya, descovy, Odefsey, J05AR03, eviplera, J05AR18, J05AR17, J05AR19, Film-coated tablet, TRUVADA - 30 COMPRESSE RIVESTITE CON FILM IN FLACONE HDPE DA 200 MG/245 MG, STRIBILD - 150MG/150MG/200MG/245MG/ - COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) - 30 COMPRESSE, EVIPLERA - 25MG RILPIVIRINA/200MG EMTRICITABINA/245MG TENOFOVIR DISOPROXIL-COMPRESSA RIVESTITA CON FILM-USO ORALE-FLACONE (HDPE) 30 COMPRESSE, GENVOYA - 150 MG / 150 MG / 200 MG /10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, DESCOVY - 200 MG/10 MG- COMPRESSA RIVESTITA CON FILM- USO ORALE- FLACONE (HDPE)- 30 COMPRESSE, ODEFSEY - 200 MG/25 MG/25 MG- COMPRESSA RIVESTITA- USO ORALE- FLACONE (HDPE) 30 COMPRESSE | UNIVERSITY HEALTH NETWORK, Gilead Sciences, Canadian HIV Trials Network | HIV infection and menopause infezione da HIV e menopausa, HIV infection and menopause infezione da HIV e menopausa, Diseases [C] - Virus Diseases [C02] | | | | |
2017-004750-42: EFFICACY AND SAFETY OF A SIMPLIFICATION TREATMENT BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS USUAL TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS WITH MULTIDRUG RESISTANCE. Eficacia y seguridad de Dolutegravir más Darunavir/cobicistat como tratamiento de simplificación frente al tratamiento habitual en pacientes infectados por el VIH-1 virológicamente suprimidos y con resistencia a múltiples fármacos. |
|
|
| Ongoing | 4 | 100 | Europe | lamivudine, Efavirenz, Nevirapine, Film-coated tablet, Coated tablet, Capsule, hard, Tablet, Rezolsta, Tivicay, Ziagen, EMTRIVA, VIREAD, kivexa, Truvada, Intelence, Edurant, Atripla, Eviplera, Reyataz, Prezista, Kaletra, Norvir, Evotaz, Isentress, Stribild, Triumeq, Genvoya, Celsentri, Descovy | FUNDACIÓ LLUITA CONTRA LA SIDA, ViiV Healthcare | HIV-1 VIH-1, HIV infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2018-004499-36: study to assess the changes in bone health after changing from a TDF based regimen to Bicetegravir-Tenofovir Alafenamide-Emtricitavine based treatment Estudio para evaluar los cambios en la salud ósea tras el paso de un régimen basado en TDF a uno basado en Bictegravir-Tenofovir Alafenamida-Emtricitavina |
|
|
| Not yet recruiting | 4 | 60 | Europe | Biktarvy, Stribild, EMEA/H/C/004449, Pastille, Tablet, Biktarvy, Atripla, Stribild, EVIPLERA, REZOLSTA, TRUVADA | Consorci Mar Parc de Salut de Barcelona, Consorci Mar Parc de Salut de Barcelona | Bone health (bone mineral density, microarchitecture and bone quality) in HIV individuals under antiretroviral treatment with tenofovir disoproxil fumarate (TDF) that change treatment to bictegravir-tenofovir alafenamide-emtricitavin (BIC) Salud ósea (densidad mineral ósea, microarquitectura y calidad ósea) en personas con VIH bajo tratamiento antirretroviral con tenofovir disoproxil fumarato (TDF) que cambia el tratamiento a bictegravir-tenofovir alafenamida-emtricitavina (BIC), bone health in persons with HIV treatment based on TDF that change the treatment to bictegravir-TAF salud ósea en personas con VIH y tratamiento antirretroviral con TDF que cambian el tratamiento a bictegravir-TAF, Diseases [C] - Virus Diseases [C02] | | | | |
2019-002829-29: Comparison of preventive treatements against bacterial STIs in PrEP users Comparaison de traitements préventifs des IST bactériennes chez les PrEPeurs |
|
|
| Not yet recruiting | 4 | 720 | Europe | Suspension for injection in pre-filled syringe, Tablet, Bexsero | INSERM ANRS, ANRS | MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, Diseases [C] - Bacterial Infections and Mycoses [C01] | | | | |
ChiCTR-IIN-17013762: A multicenter, real-world study on two oral Truvada approaches to prevent HIV infection among MSM in China |
|
|
| Recruiting | 4 | 1000 | | Two tablets of truvada 2-24 hours before each sexual intercourse, followed by two single doses of truvada, 24 and 48 hours after the frst drug intake ;One tablet of truvada every 24 hours, orally | The First Affiliated Hospital, China Medical University; The First Affiliated Hospital, China Medical University, the Mega-Projects of national science research for the 13th Five-Year Plan | HIV/AIDS | | | | |
NCT02800655: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy |
|
|
| Active, not recruiting | 4 | 100 | US | Digital Health Feedback System | University of California, San Diego, National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, GlaxoSmithKline, Proteus Digital Health, Inc. | HIV | 12/21 | 12/23 | | |
NCT03826199: Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town (Formative Study) |
|
|
| Completed | 4 | 200 | RoW | TDF-FTC, PrEP, Truvada, Counselling on PrEP in antenatal and postnatal care | University of California, Los Angeles, University of Cape Town, Desmond Tutu HIV Foundation | Hiv | 12/21 | 09/23 | | |
NCT04331704: ANCHORS Alcohol & Sexual Health Study: UH3 Project |
|
|
| Recruiting | 4 | 88 | US | PrEP acronym (pre-exposure prophylaxis), emtricitabine/tenofovir disoproxil fumarate, Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information | University of Florida, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use, Unspecified, Substance Use, Sex Behavior | 08/24 | 08/24 | | |
D2ARLING, NCT04549467: Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test |
|
|
| Completed | 4 | 244 | RoW | Lamivudine 300 MG, 3TC, dolutegravir, Emtricitabine / Tenofovir Disoproxil Pill, truvada | Fundacion IDEAA, ViiV Healthcare | Hiv, HIV-1-infection | 09/23 | 09/23 | | |
TAF4TRANS, NCT04616963: Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis |
|
|
| Active, not recruiting | 4 | 64 | US | Emtricitabine / Tenofovir Disoproxil Oral Tablet 200/300 mg, Truvada 200Mg-300Mg Tablet, Emtricitabine Tenofovir Alafenamide 200/25 mg, Descovy 200Mg-25Mg Tablet | University of California, San Diego | Hiv, Hormone Therapy | 01/24 | 01/24 | | |
DGVTAF, NCT02656511: Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection |
|
|
| Active, not recruiting | 4 | 74 | US | Dolutegravir, Tivicay, Emtricitabine/Tenofovir, Truvada | University of California, San Francisco, ViiV Healthcare, Gilead Sciences | HIV | 05/27 | 05/28 | | |
| Active, not recruiting | 4 | 240 | US | PrEP discontinuation intervention, Offering of on-demand oral PrEP, emtricitabine/tenofovir disoproxil, Truvada, Offering of STI PEP, doxycycline, Injectable PrEP, Apretude, Cabotegravir | Emory University, National Institute of Mental Health (NIMH) | HIV, STI | 02/25 | 02/25 | | |
NCT03058835: IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project |
|
|
| Active, not recruiting | 4 | 125 | US | tenofovir disoproxil and emtricitabine, Truvada tablets | Rutgers, The State University of New Jersey | PrEP Adherence Monitoring | 12/25 | 12/25 | | |
2006-004476-12: A randomised open-label study comparing the safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection. |
|
|
| Ongoing | 3/4 | 80 | Europe | Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine, Truvada, Efavirenz, Ritonavir, Atazanavir sulfate, Abacavir sulfate, Zidovudine | University of New South Wales | Chronic HIV infection | | | | |
NCT03965923: Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy |
|
|
| Active, not recruiting | 3b | 859 | RoW | Dapivirine (DPV) Vaginal Ring (VR), Truvada Tablet, Emtricitabine/Tenofovir Disoproxil Fumarate, FTC/TDF | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 06/24 | 06/24 | | |
2014-003874-17: periconceptional preventive therapy with anti-HIV drugs in women with a partner infected with HIV terapia preventiva periconcezionale con farmaci anti HIV in donne con partner infetto da virus dell’ HIV |
|
|
| Ongoing | 3 | 30 | Europe | Truvada (Emtricitabina/Tenofovir Disoproxil), Tablet, TRUVADA*30CPR RIV 200MG/245MG | National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, National Institute for Infectious Diseases "Lazzaro Spallanzani", Gilead Fellowship Program Award – HIV Section (Gilead Sciences, Italy) | Prophylaxis against HIV infection Profilassi contro l’ infezione da HIV, Preventive therapy in healthy subjects exposed to HIV Terapia preventiva in soggetti sani esposti al virus HIV, Diseases [C] - Virus Diseases [C02] | | | | |
2014-003419-12: Switch from Efavirenz/Atripla to Rilpivirine Switch da Efavirenz/Atripla a Rilpivirina |
|
|
| Ongoing | 3 | 90 | Europe | EVIPLERA, ATRIPLA, Capsule, hard, EVIPLERA, ATRIPLA | AZIENDA OSPEDALIERA SAN GERARDO, MONZA, ITALIA, Gilead Sciences Srl | HIV INFECTION INFEZIONE DA HIV, HIV HIV, Diseases [C] - Immune System Diseases [C20] | | | | |
2008-002733-70: A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK-0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA™, in Treatment-Naïve HIV Infected Patients |
|
|
| | 3 | 65 | Europe | ISENTRESS, TRUVADA, MK-0518, ISENTRESS, TRUVADA, ISENTRESS, TRUVADA | Merck & Co., Inc., Merck & Co Inc.,, Merck & Co. Inc., Laboratoires Merck Sharp & Dhome-Chibret, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., MERCK & CO., INC., MSD BV | HIV infection | | 05/11 | | |
| Ongoing | 3 | 120 | Europe | CELSENTRI, REYATAZ, NORVIR, TRUVADA, CELSENTRI, REYATAZ, NORVIR, TRUVADA | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | HIV/ HCV Coinfection | | | | |
2010-018878-21: A phase III, open-label, single centre, single-arm, pilot study to assess the feasibility of switching, individuals receiving efavirenz with continuing Central Nervous System (CNS) toxicity, to raltegravir |
|
|
| Ongoing | 3 | 40 | Europe | Isentress, Truvada (tenofovir disoproxil/emtricitabine), Isentress, Truvada, Isentress, Truvada | St Stephen\'s AIDS Trust | HIV | | | | |
| Completed | 3 | 769 | NA | Doravirine, Darunavir, Ritonavir, TRUVADA™ or EPZICOM™/KIVEXA™ | Merck Sharp & Dohme LLC | HIV-1 | 09/16 | 03/23 | | |
DISCOVER, NCT02842086 / 2016-001399-31: Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection |
|
|
| Active, not recruiting | 3 | 5399 | Europe, Canada, US | F/TAF, Descovy®, F/TDF, Truvada®, F/TAF Placebo, F/TDF Placebo | Gilead Sciences | Pre-Exposure Prophylaxis of HIV-1 Infection | 01/19 | 09/27 | | |
2019-001961-34: ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral) ANRS 173 ALTAR (ALlégement du Traitement AntiRétroviral) |
|
|
| Not yet recruiting | 3 | 360 | Europe | Film-coated tablet, , VIREAD or Tenofovir disoproxil fumarate (generic drug), STRIBILD 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg of tenofovir disoproxil fumarate or 136 mg of tenofovir), BIKTARVY bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of emtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide., ISENTRESS, TIVICAY, DESCOVY 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, GENVOYA 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide, EPIVIR or Lamivudine (generic drugs), TRUVADA or Emtricitabine and tenofovir disoproxil fumarate (Generic drug) | INSERM ANRS, ANRS | Hiv Infection Infection par le VIH, Hiv Infection Infection par le VIH, Diseases [C] - Virus Diseases [C02] | | | | |
2020-001385-11: EPICOS - Experimental clinical trial for PreventIon or COronavirus in health Care professionalS EPICOS - Ensayo para la Prevención de la Infección por COronavirus en Sanitarios |
|
|
| Ongoing | 3 | 4000 | Europe | Truvada, Hydroxychloroquine, Tablet, Truvada, Hydroxychloroquine | Plan Nacional Sobre SIDA, Instituto de Salud Carlos III | COVID-19 COVID-19, COVID-19 Infection (Prophylaxis) Infección COVID-19 (Profilaxis), Diseases [C] - Virus Diseases [C02] | | | | |
HPTN 084, NCT03164564: Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women |
|
|
| Active, not recruiting | 3 | 3224 | RoW | Oral CAB, Cabotegravir, Oral TDF/FTC, Tenofovir disoproxil fumarate/emtricitabine, Truvada, Placebo for oral CAB, Placebo for oral TDF/FTC, CAB LA, Cabotegravir long-acting injectable, Placebo for CAB LA | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/20 | 11/24 | | |
NCT04890626: Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19 |
|
|
| Completed | 3 | 356 | Europe | Emtricitabine/Tenofovir Disoproxil Fumarate 200 MG-245 MG Oral Tablet [TRUVADA], Baricitinib + dexamethasone, Dexamethasone | Instituto de Investigación Hospital Universitario La Paz | SARS-CoV-2 Infection | 07/23 | 07/23 | | |
NCT03547908 / 2018-000926-79: Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults |
|
|
| Completed | 3 | 244 | Europe, Japan, US, RoW | B/F/TAF, Biktarvy®, Placebo to match DTG, Placebo to match F/TDF, DTG, F/TDF, Truvada®, Placebo to match B/F/TAF | Gilead Sciences | HIV-1/HBV Co-Infection | 02/22 | 03/24 | | |
DOXYVAC, NCT04597424: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) |
|
|
| Active, not recruiting | 3 | 556 | Europe | Experimental: doxycycline, Bexsero® vaccine | ANRS, Emerging Infectious Diseases | Unsafe Sex, Risk-Taking | 02/23 | 09/23 | | |
| Completed | 3 | 50 | RoW | Tenofovir alafenamide, TAF, Tenofovir Disoproxil Fumarate, TDF or Truvada | University of California, Los Angeles, University of Cape Town, Desmond Tutu HIV Foundation, Gilead Sciences | Hiv | 04/23 | 09/23 | | |
2020-001426-57: A study to compare whether giving two rather than three anti-HIV medicines daily to children and young people, aged between 2 and 15 years is assafe and effective in controlling their HIV infection Ensayo para comparar si la administración de dos en vez de tres fármacos anti-VIH diariamente en niños y pacientes jóvenes entre 2 y 15 años es tan segura y efectiva en el control de su infección por VIH. |
|
|
| Not yet recruiting | 3 | 370 | Europe | DTG/3TC DT, Dovato, Tivicay PD, Tivicay, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy, Dolutegravir, Dispersible tablet, Film-coated tablet, Capsule, hard, Dovato, TIVICAY PD, TIVICAY, Triumeq, Kivexa, Ziagen, Epivir, Combivir, Retrovir, Truvada, Descovy | Fondazione Penta Onlus, ViiV Healthcare UK Limited | HIV Infection Infección por VIH, HIV Infection Infección por VIH, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 3 | 730 | US, RoW | Islatravir, MK-8591, Placebo to FTC/TDF, FTC/TDF, TRUVADA™, Emtricitabine/Tenofovir disoproxil, Emtricitabine/Tenofovir disoproxil fumarate, Placebo to ISL | Merck Sharp & Dohme LLC | HIV-I, Human Immunodeficiency Virus Type 1, Prophylaxis | 07/23 | 07/24 | | |
| Completed | 3 | 494 | Europe, Japan, US, RoW | ISL, MK-8591, FTC/TDF, Truvada, Emtricitabine/Tenofovir Disoproxil Fumarate, FTC/TAF, Descovy, Emtricitabine/Tenofovir Alafenamide, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF | Merck Sharp & Dohme LLC | HIV Preexposure Prophylaxis | 08/23 | 08/23 | | |
AXIS, NCT06138600: Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa |
|
|
| Active, not recruiting | 3 | 200 | RoW | Cabotegravir Injection [Apretude], Apretude, Tenofovir disoproxil fumarate / emtricitabine (or lamivudine), Tenemine | University of Witwatersrand, South Africa, ViiV Healthcare | HIV Infections | 10/25 | 01/26 | | |
| Not yet recruiting | 3 | 322 | Europe | Cabotegravir Tablets, for oral use., VOCABRIA, Cabotegravir Extended-Release Injectable Suspension, for intramuscular use., APRETUDE, Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use, TRUVADA, Rectal Biopsies | ANRS, Emerging Infectious Diseases | Prevention | 10/25 | 10/26 | | |
MOBILEMEN, NCT06133686: Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa |
|
|
| Not yet recruiting | 3 | 400 | NA | Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA), Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) | MRC/UVRI and LSHTM Uganda Research Unit, King's College London, London School of Hygiene and Tropical Medicine, Africa Health Research Institute, Wits Health Consortium (Pty) Ltd, University College, London, Ministry of Health, Uganda, Desmond Tutu HIV Foundation, Assistance Publique - Hôpitaux de Paris | HIV | 12/25 | 04/27 | | |
| Active, not recruiting | 3 | 15 | US | Next-generation Reader and ID-Cap System, Digital pill system, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART) | Brigham and Women's Hospital, The Fenway Institute | HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy | 07/24 | 07/24 | | |
| Completed | 3 | 36 | US | PrEPsteps, Digital pill, Truvada | Brigham and Women's Hospital, Gilead Sciences, The Fenway Institute | HIV Infections, Substance Use Disorders | 04/24 | 04/24 | | |
| Recruiting | 3 | 40 | US | Descovy or Truvada, ID-Cap System, digital pill, Beiwe | Brigham and Women's Hospital, Gilead Sciences, The Fenway Institute | HIV Infections, Substance Use, Adherence, Medication, Adherence, Treatment | 06/24 | 08/24 | | |
PURPOSE 1, NCT04994509: Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection |
|
|
| Active, not recruiting | 3 | 5368 | RoW | Oral Lenacapavir (LEN), GS-6207, Subcutaneous (SC) Lenacapavir (LEN), F/TAF, Descovy®, F/TDF, Truvada®, Placebo SC LEN, PTM Oral LEN, PTM F/TAF, PTM F/TDF | Gilead Sciences | Pre-Exposure Prophylaxis of HIV Infection | 09/24 | 07/27 | | |
PURPOSE 2, NCT04925752: Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection |
|
|
| Active, not recruiting | 3 | 3295 | US, RoW | Oral Lenacapavir (LEN), GS-6207, F/TDF, Truvada®, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only) | Gilead Sciences | Pre-Exposure Prophylaxis of HIV Infection | 01/25 | 04/27 | | |
SimpPrEP, NCT05813964: Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. |
|
|
| Recruiting | 3 | 524 | Europe, RoW | TDF/FTC 300mg/200mg fixed-dose combination tablets, Truvada, TAF/FTC 25mg/200mg fixed-dose combination tablets, Descovy | ANRS, Emerging Infectious Diseases, Chiang Mai University, Thailand, Ministry of Health, Thailand, Assistance Publique - Hôpitaux de Paris, FRANCE, Gilead Sciences | HIV/AIDS | 10/26 | 05/27 | | |
HPTN 083, NCT02720094: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men |
|
|
| Active, not recruiting | 2/3 | 4570 | US, RoW | Cabotegravir Oral Tablet, Oral cabotegravir, TDF/FTC tablets, Truvada, Placebo for TDF/FTC tablets, Placebo for Truvada, Placebo for cabotegravir oral tablet, Placebo for oral cabotegravir, CAB LA, Long acting cabotegravir, Injectable cabotegravir, Placebo for CAB LA, Placebo for long acting cabotegravir | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Gilead Sciences | HIV Infections | 05/20 | 07/24 | | |
NCT04742491: Pre-Exposure Prophylaxis for Transgender Women in the US and South America |
|
|
| Active, not recruiting | 2/3 | 307 | US, RoW | Immediate Intervention Arm Truvada in the US, Truvada, Deferred Intervention Arm Truvada in the US, Immediate Intervention Arm Truvada in Brazil, Deferred Intervention Arm Truvada in Brazil, Immediate Intervention Arm Descovy in the US, Descovy, Deferred Intervention Arm Descovy in the US | HIV Prevention Trials Network, Gilead Sciences | HIV Prevention | 09/24 | 09/24 | | |
PrEPVacc, NCT04066881: A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP |
|
|
| Enrolling by invitation | 2b | 1668 | RoW | Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48), Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48), Vaccine Group C: Saline placebo (weeks 0,4,24,48), Control PrEP:TDF/FTC once daily (weeks 0-26), Truvada, Experimental PrEP:TAF/FTC once daily (weeks 0-26), Descovy | MRC/UVRI and LSHTM Uganda Research Unit, Imperial College London, University College, London, International AIDS Vaccine Initiative, EuroVacc Foundation, Medical Research Council, South Africa, National Institute for Medical Research, Tanzania, Muhimbili University of Health and Allied Sciences, Instituto Nacional de Saúde, Mozambique, Ludwig-Maximilians - University of Munich, King's College London, Centre Hospitalier Universitaire Vaudois, Karolinska Institutet, CONRAD, Gilead Sciences | HIV Infections | 12/24 | 12/24 | | |
2008-004885-24: Essai pilote multicentrique évaluant la capacité d’une stratégie de traitement antirétroviral intermittent à maintenir une stabilité immunologique chez des patients infectés par le VIH-1, jamais traités et ayant un nombre de lymphocytes CD4 > ou = 500 par mm3. |
|
|
| Ongoing | 2 | 39 | Europe | Reyataz, Norvir, Kivexa, Truvada, Reyataz, Norvir, Kivexa, Truvada, Reyataz, Norvir, Kivexa, Truvada | Agence nationale de recherches sur le sida et les hépatites virales. ANRS. | Infection VIH | | | | |
2008-006287-11: Virologic efficacy of Maraviroc in adult naive HIV patients with HIV-RNA>= 1000 copies/ml |
|
|
| Ongoing | 2 | 60 | Europe | CELSENTRI, TRUVADA, KALETRA, CELSENTRI, TRUVADA, KALETRA | OSPEDALE S. RAFFAELE | naive HIV affected patients | | | | |
2009-016480-11: “No Nuc, No Boost” : A phase 2 pilot study of simplification by Maraviroc-Raltegravir following 6 months of treatment with Maraviroc-Raltegravir-Tenofovir-Emtricitabine in naive patients infected by CCR5 HIV-1 |
|
|
| Ongoing | 2 | 40 | Europe | Raltegravir, Maraviroc, Tenofovir/Emtricitabine, ISENTRESS, CELSENTRI, TRUVADA, ISENTRESS, CELSENTRI, TRUVADA | P Pierre Dellamonica | HIV naïve patients, CCR5 tropism, with CD4 > 200/mm3 and HIV RNA < 100 000 copy/ml. | | | | |
2014-001348-39: Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatment Ensayo clinico para medir la carga viral en el semen de pacientes VIH que no han recibido tratamiento antirretroviral previamente |
|
|
| Ongoing | 2 | 36 | Europe | EVIPLERA, STRIBILD, TRUVADA, PREZISTA, NORVIR, EVIPLERA, STRIBILD, TRUVADA, PREZISTA, NORVIR | Fundación pública andaluza para la gestión de la investigación en salud de Sevilla (FISEVI), Infectious disease department | HIV-1 infection Infección por VIH-1 | | | | |
NCT03954327: Combination Antiretroviral Therapy (cART) for PBC |
|
|
| Completed | 2 | 37 | Canada | Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Truvada, Raltegravir, Isentress, Placebo Oral Capsule [CEBOCAP], placebo | University of Alberta, Merck Sharp & Dohme LLC | Primary Biliary Cholangitis | 10/22 | 01/24 | | |
NCT04824131: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females - A Sub-study of HPTN 084 |
|
|
| Completed | 2 | 50 | RoW | Oral cabotegravir (CAB), CAB LA, Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 01/23 | 01/23 | | |
NCT04692077: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083 |
|
|
| Completed | 2 | 9 | US | Cabotegravir (CAB) tablet, CAB LA, Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 07/23 | 07/23 | | |
NCT03386578: Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum |
|
|
| Completed | 2 | 390 | RoW | Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Truvada, Behavioral HIV risk reduction package | National Institute of Allergy and Infectious Diseases (NIAID), Gilead Sciences | HIV Infections | 10/23 | 02/24 | | |
| Active, not recruiting | 2 | 330 | RoW | emtricitabine/tenofovir alafenamide, Descovy, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Truvada | Eastern Virginia Medical School, CONRAD, FHI 360, United States Agency for International Development (USAID), Gilead Sciences | Acceptability of Health Care, Adherence, Medication | 12/23 | 04/24 | | |
NCT06435026: Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 |
|
|
| Not yet recruiting | 2 | 54 | RoW | FTC/TDF 200mg/300mg, PrEP, FTC/TDF 300mg/450mg, FTC/TDF 400mg/600mg | University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, Prevention, Pregnancy | 02/25 | 02/25 | | |
NCT05957913: Effects of Antiviral Therapies on Epstein-Barr Virus Replication |
|
|
| Enrolling by invitation | 2 | 50 | US | Truvada (tenofovir/emtricitabine), TDF | Massachusetts General Hospital, Solving MS | Multiple Sclerosis | 06/24 | 12/24 | | |
| Active, not recruiting | 2 | 72 | RoW | co-formulated 300 mg TDF/ 200mg FTC, Truvada | University of Washington, University of Colorado, Denver, Kenya Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 03/24 | 01/25 | | |
PURPOSE 3, NCT06101329: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) |
|
|
| Recruiting | 2 | 250 | US | Lenacapavir Tablet, GS-6207, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF), Truvada® | Gilead Sciences, HIV Prevention Trials Network | Pre-Exposure Prophylaxis of HIV Infection | 01/28 | 01/28 | | |
PURPOSE-4, NCT06101342: Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) |
|
|
| Recruiting | 2 | 250 | US | Lenacapavir Injection, GS-6207, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Truvada® | Gilead Sciences, HIV Prevention Trials Network, National Institute on Drug Abuse (NIDA), National Institute of Allergy and Infectious Diseases (NIAID) | Pre-Exposure Prophylaxis of HIV Infection | 07/27 | 07/27 | | |
| Not yet recruiting | 1/2 | 34 | US | Tenofovir (TDF) and Emtricitabine (FTC), Truvada (Tenofovir Disoproxil Fumarate and Emtricitabine), Viread (Brand for tenofovir disoproxil fumarate), Emtriva (Brand for emtricitabine), Placebo | Children's Hospital of Philadelphia, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Human Genome Research Institute (NHGRI), Gilead Sciences, Emerson Resources, National Institutes of Health (NIH) | Aicardi Goutières Syndrome | 12/28 | 12/28 | | |
| Active, not recruiting | 1 | 15 | US | Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo | Oak Crest Institute of Science, The Miriam Hospital, Johns Hopkins University, University of California, Los Angeles, University of California, San Diego, Vanderbilt University, The University of Texas Medical Branch, Galveston, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) | HIV Prevention | 09/20 | 12/25 | | |
NCT04760691: Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW |
|
|
| Recruiting | 1 | 20 | US | Truvada alone, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), Truvada plus Leuprolide, Truvada plus Lupron, Truvada plus Estradiol 1 mg, Truvada plus low dose estrogen, Truvada plus Estradiol 6 mg, Truvada plus high dose estrogen, Estradiol 6 mg alone, Estradiol 6 mg | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Hiv, Prophylaxis, Transgender | 03/25 | 06/25 | | |
TARCoV, ChiCTR2000029468: A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | N/A | 120 | China | Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination ;LPV/r | Institute of Emergency Medicine and Disaster Medicine Sichuan People's Hospital, Sichuan Academy of Medical Sciences; Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Department of science and technology of sichuan province (2020YFS0006) | novel coronavirus pneumonia (COVID-19) | | | | |
NCT04898699: IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya |
|
|
| Not yet recruiting | N/A | 120 | NA | UrSure Rapid Urine Tenofovir Test, OraQuick Rapid HIV Self-test kit, Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®], 2-way text message reminders, HIV risk-reduction counseling | Columbia University, Impact Research & Development Organization, Research Foundation for Mental Hygiene, Inc. | HIV | 03/22 | 03/22 | | |
NCT04583267: HIV Pre-exposure Prophylaxis Implementation Study in South Korea |
|
|
| Recruiting | N/A | 200 | RoW | tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration | Yonsei University | HIV Infections | 12/22 | 12/22 | | |
| Completed | N/A | 17 | US | Suboxone, Buprenorphine Naloxone, Truvada, Pre-Exposure Prophylaxis (PrEP), Mavyret, Hepatitis C treatment | Duke University, Center for AIDS Research (CFAR), National Institute of Allergy and Infectious Diseases (NIAID) | Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C | 03/23 | 03/23 | | |
ChiCTR2200059994: A clinical research for Biktarvy following potential exposure to HIV-1 |
|
|
| Not yet recruiting | N/A | 100 | | Biktarvy is taken orally once a day. ;TDF+FTC+DTG/RAL | Guiyang public health treatment center; Guiyang public health treatment center, self-finacing | HIV/AIDS | | | | |
INSIGHT, NCT05746065: A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women |
|
|
| Completed | N/A | 3087 | RoW | PrEP, Truvada | University of Washington, Bill and Melinda Gates Foundation | HIV Infections | 08/23 | 08/23 | | |
NCT04778514: A Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Completed | N/A | 30 | RoW | Dual Prevention Pill, DPP, PrEP and combined oral contraceptive (COC) as two separate tablets, Truvada, Zinnia F | Population Council, University of Zimbabwe | HIV Infections, Contraception | 09/23 | 09/23 | | |
NCT04593680: Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men |
|
|
| Recruiting | N/A | 40 | RoW | Emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (F/TDF) and emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) | Thai Red Cross AIDS Research Centre | Drug Interaction | 10/23 | 10/25 | | |
NCT04778527: A Crossover Adherence and Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy Prevention |
|
|
| Active, not recruiting | N/A | 96 | RoW | Dual Prevention Pill, DPP, PrEP tablet and a COC as two separate tablets, Truvada, Zinnia F | Population Council | HIV Infections | 01/24 | 01/24 | | |
| Recruiting | N/A | 621 | RoW | Initiating daily oral PrEP during pregnancy, Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC), Already using daily oral PrEP at the time of pregnancy diagnosis, Initiating injectable PrEP during pregnancy, CAB-LA, Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis | University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States President's Emergency Plan for AIDS Relief, Ministry of Health, Malawi | Pre-exposure Prophylaxis, HIV Prevention, Pregnancy Related | 12/26 | 12/27 | | |
| Recruiting | N/A | 3257 | Europe | PrEP with Truvada®, Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) | ANRS, Emerging Infectious Diseases | HIV Infections | 05/24 | 10/24 | | |
ChiCTR2200061677: Impact of different antiretroviral therapy (ART) regimens on lipid metabolism in people living with HIV |
|
|
| Not yet recruiting | N/A | 180 | | EVG/c/TAF/FTC ;B/FTC/TAF ;DTG/3TC ;DTG/3TC/TDF ;DTG/FTC/TDF ;TDF/3TC/EFV | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, National Special Research Program for Important Infectious Diseases | AIDS | | | | |
| Recruiting | N/A | 50 | US | LA-CAB, Apretude, TDF/FTC, Truvada | Orlando Immunology Center | HIV Prevention | 09/24 | 09/24 | | |
BMS02, NCT04862975: Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana |
|
|
| Recruiting | N/A | 200 | RoW | Dolutegravir, Dolutegravir Sodium, DTG, Lamivudine, 3TC, Emtricitabine, FTC, Tenofovir Disoproxil Fumarate, Tenofovir DF, TDF | Duke University, The Emmes Company, LLC | Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI, HIV Infections | 12/24 | 12/24 | | |
Prep-RN, NCT06030557: PrEPared-RN, CAN Nurse-Led Management of High-risk Patients for Pre-Exposure Prophylaxis (PrEP) |
|
|
| Recruiting | N/A | 210 | US | Truvada, Descovy | CAN Community Health | Hiv Prevention, Pre-Exposure Prophylaxis (PrEP) | 07/25 | 07/25 | | |